EVIDENT Announces Alliance to Automate Digital Pathology Workflows

Evident announced an alliance with Corista, Sakura Finetek USA and Visiopharm to deliver an automated, end-to-end workflow solution for pathology in the USA. Together, the scientific leaders will combine their technologies to streamline the workflow of staining, imaging, and analyzing whole slide images with the collaboration and management needed in today’s high-volume laboratories.

Lymph node metastasis detection APP #90159. Image Credit: Visiopharm

Demand for efficient pathology and quality control of sample handling has increased in recent years. The collaboration of these technology leaders supports customers in their transition to a digital workflow by combining histopathology, digital pathology, and computational pathology.

Evident and Corista, leaders in image management solutions, previously developed a high-end scanner with a modern image management system that leverages Visiopharm’s image analysis and artificial intelligence (AI) toolset. Sakura Finetek USA and Evident have also collaborated, delivering an automated staining and whole slide imaging workflow to reduce manual tasks across pathology labs in clinical and life science organizations.

“The alliance of these four companies will help drive the adoption of a fully automated pathology system across laboratories,” said Lee Wagstaff, the Vice President of Life Science Sales and Marketing at Evident Americas. “We look forward to supporting our mutual customers with a complete end-to-end digital pathology solution to drive efficiency and reduce manual tasks as pathology testing volume ramps up.”

“Supporting pathology laboratories in driving better patient outcomes that are sustainable and effective is at the heart of what we do,” said Corista CEO Elizabeth Wingard. “This alliance will help our customers with better collaboration across their consulting and analysis workflows.”

“Working together will help move computational pathology to the forefront through a scalable and integrated system,” said Visiopharm CEO Michael Grunkin. “Our AI-driven precision pathology software integrated with our partners’ technology yields more effective, robust performance that reduces manual workflows and time-consuming tasks.”

“We are excited to offer customers the ability to enhance patient care with an end-to-end automated workflow,” added Patrick Devor, the Vice President of Sales at Sakura Finetek USA, Inc. “This alliance will enable us to increase the level of automation across histopathology, drive quality, and reduce turnaround time, which has been a goal of Sakura Finetek since 1870.”


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - NDT. (2023, September 20). EVIDENT Announces Alliance to Automate Digital Pathology Workflows. AZoM. Retrieved on June 17, 2024 from https://www.azom.com/news.aspx?newsID=61901.

  • MLA

    Evident Corporation - NDT. "EVIDENT Announces Alliance to Automate Digital Pathology Workflows". AZoM. 17 June 2024. <https://www.azom.com/news.aspx?newsID=61901>.

  • Chicago

    Evident Corporation - NDT. "EVIDENT Announces Alliance to Automate Digital Pathology Workflows". AZoM. https://www.azom.com/news.aspx?newsID=61901. (accessed June 17, 2024).

  • Harvard

    Evident Corporation - NDT. 2023. EVIDENT Announces Alliance to Automate Digital Pathology Workflows. AZoM, viewed 17 June 2024, https://www.azom.com/news.aspx?newsID=61901.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.